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A variety of cutaneous reactions have been
described in patients receiving tumor necrosis factor
alfa (TNF-a) inhibitors.1 Of particular interest in this
scenario is the development of lichen planus and
lichen planuselike eruptions. Because TNF-a is
recognized as a significant factor in the induction
of these dermatoses, their appearance after inhibi-
tion of TNF-a is perplexing.2 The leading theory
postulates that a disturbance in the balance between
inflammatory cytokines occurs with TNF-a inhibi-
tion, leading to increased expression of other cyto-
kines such as interferon.1-3 Interferon then induces
an endogenous inflammatory response that clinically
manifests as a cutaneous lichenoid eruption.1-3
Lichen striatus is an acquired inflammatory derma-
tosis that follows the lines of Blaschko.4 Blaschko
lines are invisible in normal skin but may become
apparent in various skin conditions.5 It has been
postulated that the cells along Blaschko lines contain
distinct genotypes that may ultimately permit a
unique response to stimuli such as interferon. This
heightened sensitivity to interferon is likely the un-
derlying explanation for the appearance of segmental
lichenoid reactions after treatment with TNF-a in-
hibitors. However, reports of these eruptions after
interferon are lacking, and the evidence to support
this concept is primarily substantiated by reports of
segmental lichenoid reactions after anti-TNF agents.CASE REPORT
A 64-year-oldmanwith a 5-year history of hepatitis
C presented with a linear cutaneous eruption
affecting the right lower extremity. The onset of this
cutaneous eruption occurred after the 24th week of
treatment with interferon. Before consultation withrtment of Dermatology, Texas Tech University Health Sciences
ntera and, Texas Tech University Health Sciences Center
hool of Medicine.b
ing sources: None.
icts of interest: None declared.
spondence to: Michelle B. Tarbox, MD, Texas Tech University
alth Sciences Center, Department of Dermatology, HSC
ilding 3601 4th Street Room 4A100, Lubbock, TX 79430-
00. E-mail: michelle.tarbox@ttuhsc.edu.the dermatology department, the patient had been
using triamcinolone 0.025% ointment twice a day to
affected regions with no improvement. The patient
denied history of previous treatment for hepatitis C,
including interferon. Physical examination found
grouped erythematous scaly papules arranged in a
strikingly linear distribution extending from the dor-
sal penis to the distal right plantar foot (Figs 1 to 3). A
punch biopsy of the thigh found a lichenoid lym-
phocytic infiltrate at the dermoepidermal junction
along with dyskeratotic keratinocytes and periecrine
lymphocytic infiltrate, findings consistent with lichen
striatus (Figs 4 and 5). The patient received 28 weeks
of treatment with interferon, after which it was
discontinued and was never reinitiated. The rash
completely resolved 6 months after discontinuation
of interferon 7 months after its initial appearance. He
has since had no recurrence of the eruption.
Additionally, the patient’s viral load was monitored
throughout the 28 weeks of treatment with inter-
feron. At the start of interferon therapy, viral loadwas
5,965,981 IU/mL. By week 8, viral load became
undetectable and remained so for the additional
20 weeks of therapy.DISCUSSION
A substantial portion of the medical literature is
devoted to the proposed role of interferon in the
development of lichenoid eruptions and Blaschkoid
dermatoses and even in the development of autoim-
munity itself.6-8 With the increased use of TNF-a
inhibitors, the frequency of these phenomena has
increased.1,2,9-11 Multiple studies have indepen-
dently concluded that TNF-a inhibition leads to
increased amounts of interferon, which then induces
these eruptions. This conclusion is strengthened byJAAD Case Reports 2015;1:254-6.
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Fig 1. Located on the right lower leg in a linear distribu-
tion are violaceous and erythematous papules with over-
lying tightly adherent scale.
Fig 2. Faint pink and violaceous hyperkeratotic papules
extending in a linear array from the plantar heel to the base
of the third metatarsal.
Fig 3. The linear lichenoid eruption extends to involve
the superior leg.
Fig 4. Punch biopsy shows a lichenoid lymphocytic
infiltrate at the dermoepidermal junction with dyskeratotic
keratinocytes. (Hematoxylin-eosin stain.)
Fig 5. Perieccrine lymphocytic infiltrate. (Hematoxylin-
eosin stain.)
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for triggering our patient’s lichenoid eruption.
Our claim that interferon resulted in our patient’s
lichenoid eruption is supported by several elements
of our case. It is well recognized that lichenoid drug
eruptions are delayed drug reactions, showing
delay in both timing of appearance after drug
initiation and prolongation after drug discontinua-
tion.4,12 In our patient, Lichen striatus appeared
6 months into treatment with interferon and
resolved 6 months after discontinuation; we believe
these features are most consistent with a lichenoiddrug eruption. Because idiopathic lichen striatus
spontaneously resolves in most cases, the argument
could be made that the disappearance of our
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portive of a drug reaction.4,12 However, the timing
of resolution of our patient’s reaction is more
supportive of drug-induced lichen striatus, as idio-
pathic lichen striatus resolves after an average
duration of 1 year.4,12 It is also possible that the
true inflammatory component of the rash may have
lasted less than 6 months, and the latter end of this
stated duration may have simply represented post-
inflammatory hyperpigmentation. Because follow-
up occurred after resolution of the rash, we cannot
state with certainty how long the lichen striatus truly
lasted. Rechallenge with interferon was discussed
with our patient but was not a feasible option, as he
experienced significant depression throughout the
course of treatment and expressed resistance to
rechallenge with the medication. Finally, the viral
load recorded in our patient is supportive of a
relation of lichen striatus to interferon rather than to
underlying hepatitis C. At the start of interferon
therapy, viral load was 5,965,981 IU/mL. By week 8
of therapy, viral load became undetectable and
remained so for the remaining 20 weeks of therapy.
The patient’s lichenoid eruption appeared after he
received 24 injections of interferon during this
period of an undetectable viral load. Because the
eruption appeared after introduction of interferon,
and because a 16-week aviremic period was
demonstrated, we believe the patient’s lichenoid
eruption is more likely to be related to the interferon
rather than hepatitis C.
Mosaic dermatoses (such as lichen striatus) trig-
gered by medications are notable examples of the
interaction between environmental stimuli and
genotype, which allows the upregulation of a self-
reactive lymphocytic response.11,12 In our patient,
interferon triggered a self-inflammatory response in
the cells residing along Blaschko lines, rendering
mosaicism phenotypically apparent. Although it is
well known that anti-TNF therapy can induce
segmental lichenoid reactions, direct evidence of
interferon in the induction of these cutaneouseruptions is lacking.2 We believe our case lends
direct support to the hypothesis of interferon playing
a central role in autoimmune dermatoses in the
setting of TNF-a inhibition.
The authors thank the Texas Tech University Health
Sciences Center Clinical Research Institute for their support
in publication of this manuscript.
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